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Background
S100A12 is a member of the damage-associated molecular
pattern molecules (DAMP) and expressed by activated
granulocytes exhibiting its proinflammatory capacity by
binding to the Receptor for Advanced Glycation End-
products (RAGE). The aim of this study was to evaluate
S100A12 in MWS patients before and during therapy with
Anakinra (IL1Ra) and Canakinumab (a fully human
monoclonal antibody against IL-1β).
Patients and methods
Eight patients (1 male, 7 female) with documented CIAS1
mutations (5 E311K, 2 T348M, 1 V198M) and active dis-
ease were included in this study. After Anakinra treatment
therapy was switched to Canakinumab (ACZ885).
Muckle-Wells-Syndrome Disease-Activity-Score (MWS-
DAS), SAA, CRP, ESR and S100A12 values were recorded
one day before (baseline) and during treatment with Ana-
kinra (day 30–120) and Canakinumab (day 8).
Results
MWS-DAS, and all inflammation markers fell signifi-
cantly from baseline to follow-up in both treatment
groups. S100A12 was significantly lower with Canakinu-
mab, than with Anakinra therapy (87 ± 64 ng/ml vs. 145
± 58; p < 0,05). With Canakinumab, 88% of values were
within normal limits within one week of treatment (<120
ng/ml) whereas only 50% of values reached normal range
with Anakinra. Correlation between S100A12 and MWS-
DAS as well as ESR, CRP and SAA was significant (p <
0,05).
Conclusion
S100A12 is a sensitive marker of inflammation in patients
with MWS and may be a valuable parameter to monitor
subclinical inflammation. Data indicates that treatment
with canakinumab, in contrast to anakinra, normalized
S100A12 levels in the majority of patients.
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